CompanyGPCRNasdaqSouth San Francisco, CA

Structure Therapeutics Inc.

Structure Therapeutics develops oral small molecule GPCR-targeted treatments for metabolic conditions.

SEC EDGAR ClinicalTrials.gov ir.structuretx.com

424B4Sep 28Latest SEC filing

Sep 8Latest story

September 2026

Structure Therapeutics reports new data on oral amylin and GLP-1 obesity drugs

Sep 8Clinical readoutaleniglipron Structure Therapeutics Inc.

August 2026

Structure Therapeutics doses first patients in Phase 3 obesity program for aleniglipron

Aug 6Quarterly updatealeniglipron Structure Therapeutics Inc.